Last update 20 Mar 2025

Rosuvastatin Calcium/Nebivolol Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Nebivolol/rosuvastatin, Rosuvastatin/nebivolol
Target
HMGCR x β1-adrenergic receptor
Action
inhibitors, antagonists
Mechanism
HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists)
Therapeutic Areas
Cardiovascular DiseasesEndocrinology and Metabolic DiseaseOther Diseases
Active Indication
Chronic heart failureEssential HypertensionHomozygous familial hypercholesterolemia+ [1]
Inactive Indication-
Originator Organization
Elyson Pharm Co., Ltd.Elyson Pharm Co., Ltd.
Active Organization
Elyson Pharm Co., Ltd.Elyson Pharm Co., Ltd.
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
South Korea (30 Aug 2019),
Chronic heart failureEssential HypertensionHomozygous familial hypercholesterolemia+ [1]
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC22H28CaFN3O6S
InChIKeyAVDMILNVMOXCHF-DHMAKVBVSA-N
CAS Registry147098-20-2

Related

1
Clinical Trials associated with Rosuvastatin Calcium/Nebivolol Hydrochloride
KCT0002283
/ CompletedPhase 1
A randomized, open-label, single dose, 2-way crossover study to evaluate the pharmacokinetic characteristics of EL-1401 in comparison to the co-administration of nebivolol and rosuvastatin in healthy volunteers
100 Clinical Results associated with Rosuvastatin Calcium/Nebivolol Hydrochloride
Login to view more data
100 Translational Medicine associated with Rosuvastatin Calcium/Nebivolol Hydrochloride
Login to view more data
100 Patents (Medical) associated with Rosuvastatin Calcium/Nebivolol Hydrochloride
Login to view more data
100 Deals associated with Rosuvastatin Calcium/Nebivolol Hydrochloride
Login to view more data

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic heart failure
South Korea
Elyson Pharm Co., Ltd.Elyson Pharm Co., Ltd.
30 Aug 2019
Essential Hypertension
South Korea
Elyson Pharm Co., Ltd.Elyson Pharm Co., Ltd.
30 Aug 2019
Homozygous familial hypercholesterolemia
South Korea
Elyson Pharm Co., Ltd.Elyson Pharm Co., Ltd.
30 Aug 2019
Primary hypercholesterolemia
South Korea
Elyson Pharm Co., Ltd.Elyson Pharm Co., Ltd.
30 Aug 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free